London, United Kingdom--(Newsfile Corp. - September 29, 2025) - The 2025 Global Forum of the European Group on Graves' Orbitopathy (EUGOGO) grandly opened recently in London, the United Kingdom. As a top-tier academic event in the field of diagnosis and treatment of thyroid eye disease, this forum has brought together leading experts and scholars worldwide to jointly discuss diagnostic and therapeutic standards as well as technological innovations. The "Automatic Ocular Signometer BY-O1A" developed by Shanghai Baiyi Healthcare Technology Co., Ltd. (Baiyi Healthcare), an innovative Chinese medical device enterprise, is the only medical device product has been invited from China.
EUGOGO Global TED Forum 2025 - Shanghai Baiyi Healthcare Technology Showcases Innovative Medical Technology at International Forum
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9113/268369_161148f3b463d92b_001full.jpg
As an international authoritative organization promoting clinical research and multidisciplinary diagnosis and treatment of Graves' orbitopathy (also known as thyroid eye disease), EUGOGO has consistently conducted high-quality clinical research through cross-border collaboration, formulated evidence-based guidelines, and led the development of global diagnosis and treatment standards since its establishment in 1999.
This Forum Focuses on Standardization and Precision in the Diagnosis and Treatment of Thyroid-Related Eye Diseases. Experts attending the forum generally pointed out that the current diagnosis and treatment still face common challenges such as insufficient quantitative tools and strong subjectivity in evaluation. There is an urgent need for a standardized measurement technology and evaluation method that is "objectively repeatable, accurate and traceable".
The "Automatic Ocular signometer (BY-O1A)" provided by Baiyi Healthcare has precisely provided a "Chinese solution" to this international challenge. It is reported that this device has obtained the registration certificate for innovative Class II medical devices from China National Medical Products Administration (NMPA). It can automatically measure core indicators such as exophthalmos (eyeball protrusion) and palpebral fissure width with sub-millimeter precision, effectively solving the key technical problems in standardizing clinical evaluation. Furthermore, it fills the international gap in specialized diagnostic equipment for this field and provides an innovative solution for the precise diagnosis and treatment of thyroid eye disease.
Meanwhile, with its high level of automation and intelligence, this instrument effectively reduces the professional dependence and technical threshold for this type of examination. This endows it with prominent advantages in enhancing the diagnosis and treatment capabilities of primary-level hospitals and expanding the accessibility of standardized diagnosis and treatment service which is an advantage that is highly aligned with the goal of "improving global access to diagnosis and treatment" advocated by EUGOGO.
During the forum, this technology attracted widespread attention and high praise from international authoritative experts. An expert from Moorfields Eye Hospital in the UK stated, "This technology provides an innovative solution to address the global challenge of standardizing diagnosis and treatment, and its precision and repeatability are impressive." An expert from the University Medical Center of Mainz in Germany also pointed out that this technology offers crucial technical support for disease diagnosis and the evaluation of treatment outcomes.
Recognition of its technological strength has also been translated into substantive cooperation intentions. During the conference, Baiyi Healthcare reached initial consensus with medical centers from countries such as Italy and Spain, planning to conduct multi-center clinical validation in Europe. Additionally, representatives from well-known international pharmaceutical enterprises also took the initiative to connect with Baiyi Healthcare to explore potential cooperation in clinical research and development as well as commercial applications.
The leadership of Baiyi Healthcare stated that the company is developing a multilingual version of its system and plans to jointly build an international database with EUGOGO member institutions to promote the establishment of more comprehensive evaluation standards for thyroid eye disease. In addition, the company has begun preparations for EU medical device registration which is expected to complete CE certification in 2026.
As the global medical community's demand for standardization in diagnosis and treatment continues to grow, Chinese medical technology enterprises are deeply participating in the development of international standards through independent innovation. The technological breakthrough of the "Automatic Ocular signometer (BY-O1A)" not only demonstrates the R&D (Research and Development) capabilities of China's high-end medical equipment but also supports EUGOGO's core mission of "improving the quality of life of patients with thyroid eye disease worldwide" through concrete actions, contributing Chinese wisdom to build Community of Shared global Human Health.
Contact:
Shanghai Baiyi Healthcare
https://baiyi-healthcare.com/
Tom Gan
ganyi@baiyi-healthcare.com/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268369